
|Videos|August 25, 2021
RVL Pharmaceuticals: Shifting toward ocular aesthetics
Author(s)David Hutton, Alex Delaney-Gesing
COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.
Advertisement
JD Schaub, chief operating officer at RVL Pharmaceuticals, provides an overview of how the company has shifted toward focusing on ocular aesthetics, along with the sole purpose to fully focus on UPNEEQ®, a prescription eye drop.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy
2
FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)
3
Recognizing biomarkers of Alzheimer Disease using OCTA
4
Midyear cataract check-in: What 2026 has brought to the OR and beyond
5





















